Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly To Rival Pfizer's Ibrance As Early As 2017

This article was originally published in Scrip

Executive Summary

Could Eli Lilly & Co.'s CDK 4/6 inhibitor abemaciclib beat Novartis AG's offering to market and trespass on Pfizer Inc.'s Ibrance (palbociclib) sales more than a year earlier than anticipated?


Related Content

Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review